Association between intravesical prostatic protrusion and clinical outcomes in prostatic artery embolization |
| |
Authors: | Tom Boeken Alessandro Di Gaeta Nadia Moussa Constantino Del Giudice Carole Dean Olivier Pellerin Marc Sapoval |
| |
Institution: | 1. Department of Vascular and Oncological Interventional Radiology, AP–HP, centre, Hôpital Européen Georges-Pompidou, 75015 Paris, France;2. Université de Paris, 75006 Paris, France;3. INSERM URM 970 équipe 2 Imagerie de l’Angiogenèse, 75015 Paris, France |
| |
Abstract: | PurposeTo evaluate the influence of intravesical prostatic protrusion (IPP) on clinical outcomes after prostatic artery embolization (PAE) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.Materials and methodsAll consecutive patients who underwent PAE for lower urinary tract symptoms between January 2017 and January 2019 were retrospectively included. IPP was evaluated on pre-treatment magnetic resonance imaging examination and symptoms were assessed at follow-up consultations using the international prostate symptom score (IPSS) and quality of life (QOL) questionnaire. IPPs were classified as grade 1 (< 5 mm), grade 2 (5–10 mm), or grade 3 (> 10 mm).ResultsA total of 160 consecutive men (mean age 65 ± 7.8 SD] years; range: 45–89 years), underwent PAE. The mean IPSS was 21 ± 7.3 (SD) (range: 5–35) and prostate volume 87 ± 38 (SD) mL (range: 30–200 mL). The IPP grade was 1 for 28 (28/160; 18%), 2 for 52 (52/160; 33%), and 3 for 80 (80/160; 50%) patients. There were no significant differences in IPSS at baseline between the three IPP grades. Patients with severe (grade 3) IPP had a significantly higher reduction in IPSS than those with non-severe IPP (grade 1 or 2), with estimated mean reductions of 12 ± 2.5 (SD) (range: ?4–28) and 8.3 ± 1.9 (SD) (range: ?8–21) (P = 0.02), respectively. The mean reduction in the QOL score was 3.0 for grade 3 and 2.0 for grade 1 or 2 IPP (P = 0.02).ConclusionsThe degree of IPP does not limit the efficacy of PAE in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. |
| |
Keywords: | Embolization Interventional radiology Lower urinary tract symptoms Prostatic hyperplasia Quality of life IIEF"} {"#name":"keyword" "$":{"id":"kw0150"} "$$":[{"#name":"text" "_":"International Index of Erectile Function IPP"} {"#name":"keyword" "$":{"id":"kw0040"} "$$":[{"#name":"text" "_":"intravesical prostatic protrusion IPSS"} {"#name":"keyword" "$":{"id":"kw0050"} "$$":[{"#name":"text" "_":"international prostate symptom score LUTS"} {"#name":"keyword" "$":{"id":"kw0060"} "$$":[{"#name":"text" "_":"lower urinary tract symptoms MRI"} {"#name":"keyword" "$":{"id":"kw0170"} "$$":[{"#name":"text" "_":"magnetic resonance imaging PAE"} {"#name":"keyword" "$":{"id":"kw0070"} "$$":[{"#name":"text" "_":"prostatic artery embolization PSA"} {"#name":"keyword" "$":{"id":"kw0190"} "$$":[{"#name":"text" "_":"prostate specific antigen maximum flow rate QOL"} {"#name":"keyword" "$":{"id":"kw0090"} "$$":[{"#name":"text" "_":"quality of life SD"} {"#name":"keyword" "$":{"id":"kw0100"} "$$":[{"#name":"text" "_":"standard deviation |
本文献已被 ScienceDirect 等数据库收录! |
|